Compare JPMorgan Equity Premium Income ETF (JEPI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs 10X Genomics Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.74 (market cap $45.55B), while 10X Genomics Inc trades at $81.65 (market cap $10.07B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 4.5× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 56 Days and 10X Genomics Inc for 92 Days on average.
| JEPI | TXG | |
|---|---|---|
Market Cap | $45.55B | $10.07B |
Volume | 3,820,809 | 5,657,286 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $97.74 |
52-Week Low | $55.29 | $11.48 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.73, up 0.5% with a bearish technical signal from moving averages. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and July 2026. Technical indicators show neutral oscillators with key support at $56 and resistance at $57. Recent news highlights JEPI's role in income strategies and institutional interest.
The covered-call strategy provides income but may limit upside during rallies. Institutional ownership growth signals confidence, though the bearish technical outlook and income-focused strategy suggest moderate growth potential with steady dividend income as the primary appeal.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
